Why is Boston Scientific stock up 3.4% today?

Traders Union
All News
Stocks
Boston scientific rises 3.42% today

Highlights

Boston Scientific reported earnings of $0.86 per share with a 17.5% net income margin on $5.44 billion revenue.
Greenwood Capital Associates and Rakuten Investment Management acquired 78,520 and 243,100 shares, respectively, alongside other institutional position increases.
Boston Scientific stock faces strong long-term bearish signals with short-term selling pressure and is expected to trade in a $46.7 to $50.18 range over the next five days.

Institutional buying increases after earnings beat as sentiment shifts

Boston Scientific's latest quarterly report revealed earnings of $0.86 per share and a net income margin of 17.5%, with revenue reaching $5.44 billion. Greenwood Capital Associates LLC recently acquired 78,520 shares valued at about $3,351,000, while Rakuten Investment Management Inc. purchased 243,100 shares for approximately $10,570,000. Several other institutional investors and hedge funds also updated their BSX positions.

Anton Kharitonov, expert at Traders Union, points out that Boston Scientific’s rebound followed institutional buying and strong earnings. However, he highlights that BSX still trades below key long-term averages, keeping the structure bearish. Weak trend signals and persistent negative momentum support a cautious view. Overbought oscillators may mislead given the lack of confirmation from broader trend strength. Kharitonov warns, "Until BSX reclaims its 200-day moving average and sustains positive momentum, risk of renewed downside remains significant."

Viktoras Karapetjanc, expert at Traders Union, sees robust institutional activity and solid quarterly results fueling market confidence. He points out that multiple fund inflows and sustained revenue growth keep the bullish structure intact despite technical hesitations. The latest margin performance and uptick in institutional positioning offer a platform for further gains. Karapetjanc states, "With new investors backing BSX and fundamentals intact, I see upward potential and multiple setups for the enterprising trader."

Jainam Mehta, market strategist, notes a divergence between recent price recovery and overall negative momentum signals. He believes mixed oscillator readings and MACD strength could create tactical range-trading opportunities. If BSX breaks above $49.73, a short-term breakout may attract momentum buyers. Mehta suggests, "A contrarian entry near support at $47.71 might offer favorable risk-reward if short-term sentiment shifts."

Bearish long-term bias persists despite mixed momentum signals

BSX trades below its 20-day moving average at $49.73 and the 200-day moving average at $68.14, but sits above the 50-day at $46.57. This setup signals continued long-term bearishness, some medium-term technical support, and ongoing short-term downside pressure. Immediate resistance stands at $49.73, with near-term support at $47.71. Momentum signals are mixed: MACD indicates strong buying, but ADX at 14.71 suggests weak trend intensity. Several oscillators point to oversold conditions, including RSI at 43, Stochastic RSI at 2.68, and CCI at -150.83. Bull/Bear Power (BBP) at -1.71 shows sellers still dominate short-term momentum. Despite a strong intraday recovery and a 3.42% daily advance, the price rise diverges from the generally negative momentum backdrop and bearish structural signals.

Earlier, analysts noted that Boston Scientific faced persistent downside risk and technical weakness, citing seller dominance and operational challenges. The latest analysis strengthens this cautious outlook, as mixed momentum signals and resistance below key averages suggest traders should monitor the $47.71 support level for renewed downward pressure.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.